Steven Cohen Alector, Inc. Transaction History

Point72 Asset Management, L.P.

$51 Billion
Q3 2025

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Alector, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 542 shares of ALEC stock, worth $672. This represents 0.0% of its overall portfolio holdings.

Number of Shares

542

Holding current value

$672

% of portfolio

0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$1.42 - $3.18 $769 - $1,723	542 New	542 $1,000
Q3 2024 Nov 14, 2024	SELL	$4.34 - $6.58 $2.3 Million - $3.49 Million	-529,847 Reduced 86.24%	84,538 $394,000
Q2 2024 Aug 14, 2024	SELL	$4.19 - $6.23 $339,033 - $504,100	-80,915 Reduced 11.64%	614,385 $2.79 Million
Q1 2024 May 15, 2024	BUY	$5.69 - $8.08 $3.17 Million - $4.49 Million	556,300 Added 400.22%	695,300 $4.19 Million
Q4 2023 Feb 14, 2024	SELL	$3.77 - $8.39 $2.26 Million - $5.03 Million	-599,782 Reduced 81.19%	139,000 $1.11 Million

Q3 2023 Nov 14, 2023	SELL	$5.2 - $8.77 $5.16 Million - $8.7 Million	-992,366 Reduced 57.32%	738,782 $4.79 Million
Q2 2023 Aug 14, 2023	BUY	$5.86 - $7.93 $2.33 Million - $3.15 Million	397,806 Added 29.84%	1,731,148 $10.4 Million
Q1 2023 May 15, 2023	BUY	$5.85 - $9.84 $7.8 Million - $13.1 Million	1,333,342 New	1,333,342 $8.25 Million
Q3 2022 Nov 14, 2022	BUY	$8.19 - $13.2 $894,348 - $1.44 Million	109,200 New	109,200 $1.03 Million
Q3 2020 Nov 16, 2020	SELL	$10.54 - $24.96 $3.04 Million - $7.2 Million	-288,263 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$21.87 - $33.11 $6.3 Million - $9.54 Million	288,263 New	288,263 $7.05 Million

Others Institutions Holding ALEC

# of Institutions

158

Shares Held

58M

Call Options Held

614K

Put Options Held

223K

View Full List

About Alector, Inc.

Ticker ALEC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,563,904
Market Cap $102M
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...

More about ALEC

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account